is calcium carbonate amorphous or crystalline

Please remove one or more studies before adding more. Read our, ClinicalTrials.gov Identifier: NCT01815021, Interventional Subjects receiving calcium and vitamin D supplementation at least 1 year prior to the beginning of the study. I-Day 28 (±1) - Termination of phase I: Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. The exact dosage of calcium supplementation will be determined for each subject according the known medical history. Calculation of CA will be performed to exclude hypocalcaemia (Ca<7.0 mg/dL). Dosing day will be designated "Day 0". At the end of the treatment, each group will receive the alternative formulation for another 6 weeks. [ Time Frame: 1 year ]. Conversion factor 0.25: 100% (in mg) of the elemental calcium initial total daily intake will be replaced by 25% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake). II-Day 70 (±1) - Termination of phase II: Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. I-Day 3 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. The urine sample must include the last urine, 24 hours after starting the collection. Five minutes following the oral administration, each subject will be infused intravenously with 1.5 mg of CaCl2 labeled with 42Ca over 10 min. The normal adult urine calcium/creatinine ratio is <220 mg/g. Report: Hank Williams Jr. removed from 'MNF' intro Talk with your doctor and family members or friends about deciding to join a study. II-Day 45 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. A creatinine clearance test is done on a sample of urine collected over 24 hours. A single case showed that when taken on an empty stomach, amorphous calcium carbonate absorption in the intestine was 4.6-folds higher than crystalline calcium carbonate. Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Calculation of CA will be performed. II-Day 69 (±1) by phone: Subjects will be reminded to perform 24 hour urine collection. Subjects who are non-cooperative or unwilling to sign consent form. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Results of a test to measure phosphate in urine are seldom useful on their own. Subjects will provide the container of 24 hour urine collection for Ca, P and creatinine to test calciuria. Five subjects will be instructed to take XXX tablets in the morning before having a meal, XXX in midday before having a meal and XXX in the evening before having a meal. Get the latest research information from NIH: You have reached the maximum number of saved studies (100). Get the latest research information from NIH: You have reached the maximum number of saved studies (100). The replacement of CCS with ACC will be calculated according to the following formula: NTDC = ITDC - [0.1×ITDC (mg CCS)] + [0.05×ITDC (mg ACC)], *ITDC - Initial total daily calcium intake (mg), **NTDC - New total daily calcium intake (mg). This rule assumes that normal albumin equals 4.0 g/dL and normal calcium is 10.0 mg/dL. Blood tests will be performed to define serum calcium, P and albumin baseline values. Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Phase II Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The initial assessment of hypocal¬cemia is usually based on the measurement of serum total calcium corrected for albumin concentration. The exact dosage of calcium supplementation for each subject will be determined by the known medical history. Subjects with other severe chronic disease requiring long-term therapy. Phase II To test the hypothesis that treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL). Subjects will be asked about symptoms and signs related with a change in serum calcium levels (tetany, facial grimacing, paresthesias, muscle aches, arrhythmia, depression). Subjects will be asked about any side effects or AEs that may have occurred and changes in concomitant medications since their last visit. Subjects who provide written informed consent to participate in the study. Conversion factor 0.75: 50% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 37.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake). If CA < baseline, then 10% (in mg, calculated out of the initial total daily intake) of elemental calcium will be replaced by 7.5% of elemental calcium from ACC (in mg, calculated out of the initial total daily intake). II-Day 56 (±1): Subjects will arrive at the Clinical Research Center and their serum calcium, P and albumin levels will be tested. Understanding of the shape-preserving crystallization from transient amorphous precursors to crystalline products in biomineralization makes it possible to produce topologically complex morphologies that defy crystallographic controls. Adjustments of ACC or CCS intake will be performed if necessary. Calculation of CA will be performed. COVID-19 is an emerging, rapidly evolving situation. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. Adjustments of ACC or CCS intake will be performed if necessary. If CA values are within the desired target range (7.0-10.0 mg/dl), subjects will continue to take the calcium doses that were instructed on I-day 0. Subjects will be asked to fill out a food and medication diary for 3 consecutive days to evaluate their daily dietary calcium intake. Any acute medical situation (e.g. Calcium (albumin corrected) serum values below 7.0 mg/dL or above 10.0 mg/dL, Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), Subjects with impaired renal function (glomerular filtration rate, ≤40 mL/min).